Clinical Trial Update: IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial conducted by The University of Hong Kong is evaluating intravenous immunoglobulin plus rituximab versus rituximab alone as first-line t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pemphigus

Drugs mentioned

• Intravenous immunoglobulin (IVIG) (intravenous immunoglobulin)
• Rituxan (rituximab)

Snippet

Sponsor: The University of Hong Kong | Conditions: Pemphigus | Phase 2 | Status: ACTIVE_NOT_RECRUITING